Review Article

Development of an Iranian National Clinical Practice Guideline for the Prevention, Diagnosis, and Treatment of Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients

Abstract

Cytomegalovirus (CMV) infection is one of the most important causes of mortality and morbidity in hematopoietic stem cell transplant (HSCT) recipients. There are many guidelines for CMV prevention, diagnosis, and treatment. However, in resource-limited settings, the implementation of international guidelines is constrained by some differences in epidemiology, diagnostic methods, and drug availability. This study develops a national guideline for CMV management based on the healthcare context in Iran. The Guideline Development Group (GDG) is a multidisciplinary team that consists of experts in hematology, oncology, infectious diseases, virology, pharmacology, epidemiology, and methodology that develops the guideline. To have a systemic approach, a literature review was conducted based on relevant studies about CMV management in HSCT recipients from 2000 to 2025. The quality of evidence is assessed through the GRADE methodology and Delphi process. The guideline includes recommendations for risk stratification, surveillance, diagnostic methods, prophylactic strategies, and management of resistant/refractory infections. However, considering limited access to anti-viral agents such as Letermovir in Iran, alternative approaches are designed to have a feasible and effective protocol. Therefore, the guideline integrates international evidence with local healthcare real settings to provide an implementable protocol for CMV management. The context-adapted guideline results in optimized resource utilization and reduces variability in practice. Considerably, the establishment of a national registry system and periodic updates can strengthen CMV control in Iran healthcare system.

 

1.Umarovich BM. Developing of viral infections in hematopoietic stem-cell transplant (HSCT) recipients. WOM. 2025; 3(5): 568-573.
2. Centers for Disease Control and Prevention; Infectious Diseases Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2000;6(6a):7-83.
3. Jakharia N, Howard D, Riedel DJ. CMV Infection in Hematopoietic Stem Cell Transplantation: Prevention and Treatment Strategies. Curr Treat Options Infect Dis. 2021; 13(3): 123-140.
4. Ljungman P, Boeckh M , Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017; 64(1):87-91.
5. Valadkhani B, Kargar M, Ashouri A, et al. The risk factors for cytomegalovirus reactivation following stem cell transplantation. J Res Pharm Pract. 2016;5(1):63-9.
6. Chung H. CMV infections after HSCT: prophylaxis and treatment. Blood Res. 2025;60(1):33.
7. Hiskey L, Madigan T, Ristagno EH, et al. Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review. Front Pediatr. 2022;10:1039938.
8. Dykewicz CA. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. Clin Infect Dis. 2001;33(2):139-44.
9. Ljungman P, de la Camara R , Robin CH, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(8):e260-e272.
10. Organization WH. WHO Handbook for Guideline Development, 2nd edition. Geneva, Switzerland: World Health Organization; 2014.
11. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6.
12. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182(18):E839-42.
13. Ford BA. The Delphi Technique: Making Sense of Consensus. Practical Assessment. Res Eval. 2007;12(10):1-8.
14. Silva F, Martins A , Ferraz P, et al. [Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients]. Acta Med Port. 2024; 37(10):733-740.
15. Keyvani HS, Taghinezhad Saroukalaei S, Mohseni AH. Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed Patients. Jundishapur J Microbiol. 2016; 9(5): e31733.
16. Styczyński J. Prophylaxis vs preemptive therapy in prevention of CMV infection: new insight on prophylactic strategy after allogeneic hematopoietic cell transplantation. Acta Haematologica Polonica. 2020; 51(1):17-23.
17. Olayemi E, Asare EV, Benneh-Akwasi Kuma AA. Guidelines in lower-middle income countries. Br J Haematol. 2017; 177(6): 846-854.
18. Jones C,. Ritchwood TD, Taggart T. Barriers and Facilitators to the Successful Transition of Adolescents Living with HIV from Pediatric to Adult Care in Low and Middle-Income Countries: A Systematic Review and Policy Analysis. AIDS Behav. 2019; 23(9):2498-2513.
19. Oshnouei S, Asadi-Lari M , Jebraeily M, et al. Epidemiological Profile of Adult Hematopoietic Stem Cell Transplantation for Malignant Diseases: Experience from a Reference Service in Urmia, Iran (2010-2024). Med J Islam Repub Iran. 2025; 39: 89.
20. Emery V, Zuckerman M, Jackson G, et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013;162(1): 25-39.
21. Piñana JL, Giménez E, Vázquez L, et al. Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC). Mediterr J Hematol Infect Dis, 2024; 16(1): e2024065.
IssueVol 20 No 3 (2026) QRcode
SectionReview Article(s)
Keywords
Cytomegalovirus; CMV; Hematopoietic stem cell transplantation; Hematopoietic stem cell transplant (HSCT); Guideline; Iran healthcare system
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Esmailpour N, Janbabaei G, Rostami T, Arjmand B, Mirzaei A, Razaghi H, Fekri S, Alijani N, Arjmand R. Development of an Iranian National Clinical Practice Guideline for the Prevention, Diagnosis, and Treatment of Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients. Int J Hematol Oncol Stem Cell Res. 2026;20(3):331-335.